The two-year ban on Novo Nordisk from the Association of the British Pharmaceutical Industry (ABPI) activities due to significant violations of its Code of Practice has officially ended.
Novo Nordisk gained full ABPI participation by undergoing extensive checks from the Prescription Medicines Code of Practice Authority (PMCPA) on its governance system and compliance processes. The company disclosed full details about the initial case through its website.
The ABPI Board received evidence through independent PMCPA audit reports which allowed it to verify that Novo Nordisk made fundamental and enduring changes to comply properly with the strict industry standards in the ABPI Code of Practice.
Richard Torbett from the ABPI emphasized that “The UK maintains globally esteemed policies to determine pharmaceutical conduct which are represented by the ABPI Code of Practice.” The peers of Novo Nordisk held the company responsible when it failed to meet industry standards during 2021 The ABPI Board successfully implemented its requirements during the last two years and I am delighted to accept Novo Nordisk back into membership activities with the ABPI.
The PMCPA publicly chastised Novo Nordisk twice during the audit that was started as a result of the suspension for other code breaches, including failing to accurately document and characterize payments it made to patients and journalists.
Novo Nordisk has operated substantially within the UK for more than fifty years with continued dedication to defeat serious chronic diseases while anticipating full membership in the ABPI.
